RudaCure Inc. has today completed the 专利申请 for the 滴眼液 formulation composition of RCI001.
This 滴眼液 composition overcomes the physicochemical limitations of RCI001 by specifying the types and ratios of excipient components, thereby enhancing the stability of the drug.
The 专利 was filed through Jin International Patent & Law Firm, which has expertise in 眼科 专利s. International 专利s, including PCT applications, are planned to be filed sequentially.